Merry Life Biomedical Co., Ltd., a Taiwan-based biomedical company, has registered a placebo-controlled clinical trial to test TML-6, a synthetic curcumin analog, in people with early Alzheimer's disease, according to a filing posted on ClinicalTrials.gov (NCT07612150). The trial is designed to run 52 weeks and will assess whether the oral drug slows, stops, or improves cognitive and functional decline compared with placebo, per the registration, which was first posted on May 28, 2026, with an estimated completion date of July 31, 2028. The study has a data monitoring committee and is regulated by the FDA as a drug trial, according to the filing. Unlike the antibody infusions currently approved for early Alzheimer's, which target amyloid plaques directly, TML-6 is described in the registration and in the company's own materials as working through what it calls an upstream autolysosomal targeting mechanism, intended to activate the cell's internal waste-clearance process known as autophagy. The compound was developed from a screen of candidate molecules and was found in earlier animal studies to reduce amyloid buildup and inflammation in two Alzheimer's animal models, according to a 2024 company announcement reporting FDA clearance of an earlier-stage trial of the same drug. That Phase 1 safety and dosing trial, which the company said began in 2024 at a Los Angeles hospital, has not yet produced published human data available to Dementias Today. No results, published or otherwise, from human testing of TML-6 have been identified. The new trial that is the subject of this article has not begun reporting outcomes, so nothing is yet known about how the drug performs, or whether it is safe, in the larger group of patients now being recruited.